Myriad Reports 17 Percent Third Quarter Revenue Growth | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday a 17 percent year-over-year increase in its revenues driven by its hereditary cancer tests.

For the three months ended March 31, Myriad reported total revenues of $182.9 million, up from $156.5 million in the third quarter of fiscal year 2013. The firm easily beat the consensus analysts' estimate of $175.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.